Venture Engineering
A New Venture Process. Power Brokers and Transformative Technologies.

We look for life science startups that have platform technologies that transform or disrupt large markets and enable multiple deals and fast exits.

Power teams. Portfolio company stakeholders and management teams are built from the power brokers within each company’s industry whose credibility, connections and actions lift the value of each company and prime them for early exits.

What Is Venture Engineering?

Venture Engineering is a process by which startups are optimized and accelerated. We build successful companies from inception through acquisition.

Step 1. Engage a Venture Engineer and trickle in seed capital. The Venture Engineering process starts with a small investment into a startup with an emerging technology from a very small team of 1 to 3 founding inventors and one Venture Engineer acting as interim CEO. The technology must be a patent protected, scalable platform and transformative or disruptive to a large market.

Step 2. Engage a Navigator. We engage a Triple Sharp Venture Engineering-trained Navigator to guide the CEO and team through the Venture Engineering process from inception to exit. Their job is to keep the team and stakeholders engaged, on process and on plan. Each Navigator keeps their finger on the pulse of 2–4 portfolio companies. Each month they briefly and transparently report each company’s progress to LPs and GPs simultaneously.

Step 3. The Venture Engineering Process. The Venture Engineer leads interviews of hundreds of customers and power brokers from which an optimized path to the market is defined and the most important relationships and best-in-class teams are built. The people we engage are deeply embedded and empowered within the industry that each portfolio company is striving to access. They have the power to deliver strategic deals and acquisitions. By the time Series A investments are made, we have the best team, a clear plan and relationships with prospective acquirers and partners. Thus, the Venture Engineering process actively addresses the most common causes of startup failure: inefficient use of time and capital; technology, product and market adoption mistakes (no pivots needed after the Venture Engineering process); and leadership teams that lack engaged power brokers. As the opportunity is de-risked and optimized, we invest up to $500K into each company and actively raise the additional capital needed to build the business.

Step 4. Exit Early. As soon as a 10X or greater bump in valuation is achieved, we usually seek to exit via a sale to a strategic, a private equity transaction or IPO. If any investments go long, then our investors will have the opportunity to participate through a follow-on fund or co-investment.


Investment Thesis




Focus and Pipeline





The Impact of Venture Engineering Funds



Social Impact Assessment

The positive economic and financial impact of the Venture Engineering approach is amongst highest within capital markets. It solves the societal problems of getting a wide range of technologies into the marketplace.

  • Determine the company’s potential to achieve the SDGs and create a lasting impact
  • Identify interconnectedness
  • More technologies make it to a world in need
  • Drive down the cost of healthcare
  • High quality jobs creation engine


Convening Power

We optimize a company’s strategic position and introduce them to members of our community who can advance corporate responsibility, capitalize businesses and open channels for international expansion.


Healthcare Events and Delegation Visits

ICV Philadelphia 2017: Healthcare Innovation Forum at Jefferson
ICV San Francisco 2018: Healthcare Innovation Forum at UCSF
ICV Manhattan 2017: Investing in African Health Systems
ICV Geneva 2018: Investing in African Health Systems
ICV Delegation Visit to China
ICV Delegation Visit to Japan

Management Team

We Work With Luminaries. A small team of generalist science, business, economic and financial advisors will be recruited from life science luminaries. The Venture Engineering process delivers the most relevant investment advice from the most important people in the business area of each portfolio company. Our advisors are specialists relative to each investment.
Gary MagnantGary Magnant is a Boston-based serial biotechnology entrepreneur with a successful track record of starting, building and selling life science companies for more than 25 years. He conceived of and developed the Venture Engineering process and principles used by the Fund to manage portfolio company risks, build power-broker teams and exit faster than Venture Capital funds. Gary is the brainchild and co-founder of several successful biotech companies, including Owl Scientific (assigned by ThermoFisher, NYSE: TMO), Sage Science (Beverly, MA) and Thrive Bioscience (Wakefield, MA). He was also a co-founder of two venture-backed startup companies, ActivBiotics (>$100M invested) and ThermoCeramix ($>10M invested) which failed under the Venture Capital model and drove much of Gary’s inspiration for a better early stage investment model.

Gary is currently interim CEO and Venture Engineer at TriBiotica, a Triple Sharp portfolio company. He is a former chairman and member of the Board of Trustees of Stoneridge Montessori (now Harborlight Montessori), and a recipient of the institution’s most prestigious community service award, The Hallowell Award. Gary is the inventor on numerous life science and advanced materials patents, including a patent issued in 2017 covering an advanced cell and tissue culture systems.

Irwin HellerIrwin Heller was Managing Partner of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC for six years. Irwin’s practice includes a diversified clientele ranging from start-up to publicly traded entities.

He is involved with joint ventures, product development and marketing agreements designed to advance the interests of multiple parties. Irwin serves as a Board Advisor to BiOWiSH Technologies Inc., and as a Member of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Boston office.

Irwin is a past Trustee of Tufts University and served as the President and Trustee of Temple Beth Elohim of Wellesley. He also served as a Trustee of the Wang Center and is a founder and Board member of Commonwealth Shakespeare Company. He is admitted to practice in Massachusetts and is a Member of the American, Massachusetts and Boston Bar Associations. Irwin has a B.A. from Tufts University and J.D., cum laude, from Columbia University Law School.

W. Adam HillW. Adam Hill is the Chief Technology Officer of Triple Sharp Venture Engineering, LLC. He is focused on positively impacting patients’ lives and bringing efficiency and effectiveness to discovering new medicines.

Adam is a pioneer in the implementation of new technologies to effect greater efficiencies in life sciences. Prior to joining Triple Sharp, Adam served as a long-time head of drug screening for Novartis, one of the top pharmaceutical companies in the world. In this role, Adam advanced new compounds into clinical development and evaluated new drug discovery technologies. He also served as a managing scientist at Millennium Pharmaceuticals and Schering-Plough.

Adam received his D. Phil, Chemistry & Pharmacology, from the University of Oxford and conducted post-doctoral research at Harvard University and the University of Connecticut.
RobertSmithICVRobert Smith is the founder of ICV. He entered Wall Street over 20 years ago with lessons passed down from four generations of family members who worked in the investment industry before him. For more than a decade, Robert has allocated capital on behalf of and co-invested with Family Offices. Over the course of his career, he managed sales and trading teams at leading financial institutions, where he built a Fund Investor network and led in profitability at three firms: once while working in a trading capacity at the world’s largest market making firm and twice while working in an equity capital markets capacity at boutique investment banks. In 2014, Robert founded ICV to bring together his network of Family Offices and Fund Investors to evaluate opportunities that create a social impact beyond a financial return. Robert serves as Business Strategy Advisor to New Frontier Bio, a multi-asset holding company, which leverages the long-term involvement of the Kennedy family in healthcare to identify, finance and develop novel medical technologies from inception through clinical proof of concept. He serves as a member of the President’s Advisory Board of Thomas Jefferson University and Jefferson Health, 16th on U.S. News & World Report’s 2017-2018 Best Hospitals Honor Roll. Robert is Senior Advisor for Fundraising and Partnerships to the Permanent Secretariat of the World Summit of Nobel Peace Laureates, a platform to consolidate peace efforts and strengthen global security, monitor and support the Nobel Peace Laureates, and engage the minds of young people and citizens on real matters that broaden vision and open up new horizons for more peaceful and compassionate thinking. He is a member of the Advisory Council of Represent.Us, which brings the left and the right together to create positive change for American democracy. He serves as a member of the board of organizations focused on youth development, including the Chaeli Foundation, Childhood Cancer Kids, The Children’s Village and Tuesday’s Children. Robert is Vice President and serves on the Board of Directors of the Harmon Foundation, a private foundation established in 1922 by his great, great grandfather, William E. Harmon, who operated the largest real estate company in the world at the turn of the 20th century, created the mortgage and college loans, fueled the Harlem Renaissance and donated to thousands of nonprofits over his lifetime “to bring smiles and tender thoughts to the great in heart in high and low places, and to comfort and cheer those who do exceptional things or suffer.”


“Goodness is the only investment that never fails.”

 – Henry David Thoreau